# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 12, "Diabet Med .", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasJournal> \"Diabet Med .\"."
1, PublicationYear, 13, 17, "2014", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasPublicationYear> \"2014\"."
2, Linagliptin, 98, 109, "Linagliptin", "", 
23, Title, 98, 327, "Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone : a 24 - week randomized , double - blind study .", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasTitle> \"Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone : a 24 - week randomized , double - blind study .\"."
104, WeightGain, 145, 156, "weight gain", "", 
12, Hypoglycemia, 160, 173, "hypoglycaemia", "", 
19, Precondition, 177, 277, "patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone", "", 
15, Type2Diabetes, 191, 206, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_57359> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
17, Metformin, 251, 260, "metformin", "", 
18, Pioglitazone, 265, 277, "pioglitazone", "", 
20, Duration, 282, 291, "24 - week", "", "<http://ctro/data#ClinicalTrial_57359> <http://ctro/data#hasCTduration> \"24 - week\"."
21, Randomized, 292, 302, "randomized", "", "<http://ctro/data#ClinicalTrial_57359> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
22, DoubleBlind, 305, 319, "double - blind", "", "<http://ctro/data#ClinicalTrial_57359> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
24, Author, 328, 335, "Bajaj M", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasAuthor> \"Bajaj M\"."
25, Author, 344, 352, "Gilman R", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasAuthor> \"Gilman R\"."
26, Author, 355, 362, "Patel S", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasAuthor> \"Patel S\"."
27, Author, 365, 386, "Kempthorne - Rawson J", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasAuthor> \"Kempthorne - Rawson J\"."
28, Author, 389, 411, "Lewis - D ' Agostino D", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasAuthor> \"Lewis - D ' Agostino D\"."
29, Author, 414, 423, "Woerle HJ", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasAuthor> \"Woerle HJ\"."
30, USA, 492, 494, "TX", "", "<http://ctro/data#Population_57375> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
36, ObjectiveDescription, 504, 713, "To investigate the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone .", "", "<http://ctro/data#ClinicalTrial_57359> <http://ctro/data#hasObjectiveDescription> \"To investigate the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone .\"."
3, Linagliptin, 585, 596, "linagliptin", "", 
35, Precondition, 600, 711, "patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone", "", "<http://ctro/data#Population_57375> <http://ctro/data#hasPrecondition> \"patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone\"."
16, Type2Diabetes, 614, 640, "Type   2 diabetes mellitus", "", 
31, Metformin, 685, 694, "metformin", "", 
33, Pioglitazone, 699, 711, "pioglitazone", "", 
37, Multicenter, 735, 749, "multi - centre", "", "<http://ctro/data#ClinicalTrial_57359> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
39, Randomized, 764, 774, "randomized", "", 
40, DoubleBlind, 777, 791, "double - blind", "", 
41, Placebo, 794, 801, "placebo", "", 
4, Linagliptin, 831, 842, "linagliptin", "", "<http://ctro/data#Medication_57425> <http://ctro/data#hasDrug> <http://ctro/data#Linagliptin>."
48, DoseValue, 843, 844, "5", "", "<http://ctro/data#Medication_57425> <http://ctro/data#hasDoseValue> \"5\"."
49, mg, 847, 849, "mg", "", "<http://ctro/data#Medication_57425> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
50, Frequency, 850, 860, "once daily", "", "<http://ctro/data#Intervention_57401> <http://ctro/data#hasFrequency> \"once daily\"."
51, NumberPatientsArm, 869, 872, "183", "", "<http://ctro/data#Arm_57383> <http://ctro/data#hasNumberPatientsArm> \"183\"."
42, Placebo, 879, 886, "placebo", "", "<http://ctro/data#Medication_57432> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
52, NumberPatientsArm, 895, 897, "89", "", "<http://ctro/data#Arm_57392> <http://ctro/data#hasNumberPatientsArm> \"89\"."
32, Metformin, 915, 924, "metformin", "", 
34, Pioglitazone, 929, 941, "pioglitazone", "", 
53, TimePoint, 985, 993, "baseline", "", "<http://ctro/data#Arm_57392> <http://ctro/data#hasNumberPatientsArm> \"89\"."
56, HbA1c, 997, 1017, "glycated haemoglobin", "", 
57, HbA1c, 1020, 1025, "HbA1c", "", 
140, Duration, 1034, 1044, "24   weeks", "", 
106285, AggregationMethod, 1061, 1094, "placebo - corrected adjusted mean", "", 
58, HbA1c, 1112, 1117, "HbA1c", "", "<http://ctro/data#Endpoint_57465> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
62, TimePoint, 1123, 1131, "baseline", "", 
55, TimePoint, 1135, 1145, "24   weeks", "", 
106287, DiffGroupAbsValue, 1150, 1153, "- 6", "", "<http://ctro/data#DiffBetweenGroups_57551> <http://ctro/data#hasDiffGroupAbsValue> \"- 6\"."
106289, SdErrorDiff, 1156, 1157, "1", "", "<http://ctro/data#DiffBetweenGroups_57551> <http://ctro/data#hasStandardErrorDiff> \"1\"."
79861, Millimoles_per_mole, 1160, 1170, "mmol / mol", "", "<http://ctro/data#Endpoint_57465> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_mole>."
67, Reduction, 1175, 1181, "0 . 57", "", 
148, SdErrorChangeValue, 1184, 1190, "0 . 13", "", 
69, Percentage, 1193, 1194, "%", "", 
75820, PvalueDiff, 1199, 1213, "P  <  0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_57551> <http://ctro/data#hasPvalueDiff> \"P  <  0 . 0001\"."
75822, SubGroupDescription, 1221, 1268, "patients with baseline HbA1c ≥  53   mmol / mol", "", "<http://ctro/data#Outcome_57565> <http://ctro/data#hasSubGroupDescription> \"patients with baseline HbA1c ≥  53   mmol / mol\". <http://ctro/data#Outcome_57592> <http://ctro/data#hasSubGroupDescription> \"patients with baseline HbA1c ≥  53   mmol / mol\"."
79862, Millimoles_per_mole, 1258, 1268, "mmol / mol", "", 
74, BaseLineValue, 1271, 1276, "7 . 0", "", 
75, Percentage, 1277, 1278, "%", "", 
76, PercentageAffected, 1283, 1289, "32 . 4", "", "<http://ctro/data#Outcome_57565> <http://ctro/data#hasPercentageAffected> \"32 . 4\"."
5, Linagliptin, 1311, 1322, "linagliptin", "", 
77, PercentageAffected, 1333, 1339, "13 . 8", "", "<http://ctro/data#Outcome_57592> <http://ctro/data#hasPercentageAffected> \"13 . 8\"."
44, Placebo, 1349, 1356, "placebo", "", 
78, HbA1c_target, 1372, 1383, "HbA1c <  53", "", "<http://ctro/data#Endpoint_57560> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
79863, Millimoles_per_mole, 1386, 1396, "mmol / mol", "", 
79, ResultMeasuredValue, 1399, 1404, "7 . 0", "", 
80, Percentage, 1405, 1406, "%", "", 
106291, AggregationMethod, 1411, 1421, "odds ratio", "", 
106290, DiffGroupAbsValue, 1424, 1430, "2 . 94", "", "<http://ctro/data#DiffBetweenGroups_57619> <http://ctro/data#hasDiffGroupAbsValue> \"2 . 94\"."
166, PvalueDiff, 1433, 1447, "P  =  0 . 0033", "", "<http://ctro/data#DiffBetweenGroups_57619> <http://ctro/data#hasPvalueDiff> \"P  =  0 . 0033\"."
106284, AggregationMethod, 1456, 1489, "placebo - corrected adjusted mean", "", 
60, TimePoint, 1509, 1517, "baseline", "", 
83, FastingPlasmaGlucose, 1521, 1543, "fasting plasma glucose", "", "<http://ctro/data#Endpoint_57628> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
61, TimePoint, 1547, 1556, "week   24", "", "<http://ctro/data#Outcome_57633> <http://ctro/data#hasTimePoint> \"week   24\". <http://ctro/data#Outcome_57660> <http://ctro/data#hasTimePoint> \"week   24\"."
106286, DiffGroupAbsValue, 1561, 1569, "- 0 . 57", "", "<http://ctro/data#DiffBetweenGroups_57687> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 57\"."
106288, SdErrorDiff, 1572, 1578, "0 . 26", "", "<http://ctro/data#DiffBetweenGroups_57687> <http://ctro/data#hasStandardErrorDiff> \"0 . 26\"."
88, Millimoles_per_litre, 1581, 1589, "mmol / l", "", "<http://ctro/data#Endpoint_57628> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
85, Reduction, 1594, 1600, "10 . 4", "", 
175, SdErrorChangeValue, 1603, 1608, "4 . 7", "", 
89, Mg_per_deciliter, 1611, 1618, "mg / dl", "", 
75823, PvalueDiff, 1623, 1637, "P  =  0 . 0280", "", "<http://ctro/data#DiffBetweenGroups_57687> <http://ctro/data#hasPvalueDiff> \"P  =  0 . 0280\"."
91, EndPointDescription, 1659, 1681, "serious adverse events", "", "<http://ctro/data#EndPointDescription_57697> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_57696> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_57697>."
92, PercentageAffected, 1686, 1691, "2 . 2", "", "<http://ctro/data#Outcome_57701> <http://ctro/data#hasPercentageAffected> \"2 . 2\"."
6, Linagliptin, 1699, 1710, "linagliptin", "", 
93, PercentageAffected, 1715, 1720, "3 . 4", "", "<http://ctro/data#Outcome_57728> <http://ctro/data#hasPercentageAffected> \"3 . 4\"."
45, Placebo, 1728, 1735, "placebo", "", 
13, Hypoglycemia, 1761, 1774, "hypoglycaemia", "", "<http://ctro/data#Endpoint_57755> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
94, PercentageAffected, 1787, 1792, "5 . 5", "", "<http://ctro/data#Outcome_57760> <http://ctro/data#hasPercentageAffected> \"5 . 5\"."
7, Linagliptin, 1802, 1813, "linagliptin", "", 
95, PercentageAffected, 1824, 1829, "5 . 6", "", "<http://ctro/data#Outcome_57787> <http://ctro/data#hasPercentageAffected> \"5 . 6\"."
47, Placebo, 1839, 1846, "placebo", "", 
96, ObservedResult, 1855, 1884, "No meaningful changes in mean", "", 
194, Mean, 1880, 1884, "mean", "", 
11, BodyWeight, 1885, 1896, "body weight", "", 
96, ObservedResult, 1897, 1924, "were noted for either group", "", 
8, Linagliptin, 1941, 1952, "Linagliptin", "", 
99, ConclusionComment, 1941, 2193, "Linagliptin as add - on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control , without an additional risk of hypoglycaemia or weight gain ( Clinical Trials Registry No : NCT 00996658 ) .", "", "<http://ctro/data#ClinicalTrial_57359> <http://ctro/data#hasConclusionComment> \"Linagliptin as add - on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control , without an additional risk of hypoglycaemia or weight gain ( Clinical Trials Registry No : NCT 00996658 ) .\"."
97, Metformin, 1976, 1985, "metformin", "", 
98, Pioglitazone, 1990, 2002, "pioglitazone", "", 
14, Hypoglycemia, 2116, 2129, "hypoglycaemia", "", 
200, WeightGain, 2133, 2144, "weight gain", "", 
202, UK, 2290, 2292, "UK", "", 
100, PMID, 2351, 2359, "24824197", "", "<http://ctro/data#Publication_57352> <http://ctro/data#hasPMID> \"24824197\"."
